Please login to the form below

Not currently logged in
Email:
Password:

Barry Labinger joins Biothera Pharmaceutical

Brings experience from Human Genome Sciences and 3M Pharmaceuticals
Biothera Pharmaceutical Barry Labinger

US biotech company Biothera Pharmaceutical has appointed Barry Labinger as its new chief executive officer.

Labinger has nearly three decades of pharmaceutical and biotech industry experience, with roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals and Immunex.

His experience with oncology drug development will be particularly useful to the Minnesota-based firm, which is developing a novel cancer immunotherapy.

Richard Mueller, chairman of the board at Biothera Holding Corp, said: “Barry has strong leadership and management skills to take Biothera Pharmaceutical forward and realise the full potential of Imprime PGG, the company's first-in-class immune modulator, which we believe is the next step in immune oncology.

“We are delighted to have such an accomplished executive lead the company through the next phase of its development.”

Labinger most recently served as executive vice president and president, Biosciences Division, at Emergent BioSolutions Inc., where he was responsible for all aspects of product development, manufacturing, and commercialisation.

14th December 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics